Page last updated: 2024-09-05

s 16020-2 and Neoplasms

s 16020-2 has been researched along with Neoplasms in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (50.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Awada, A; Bleiberg, H; Brillanceau, MH; Calvo, F; De Valeriola, D; Dosquet, C; Eftekhary, P; Gerard, B; Giacchetti, S; Giroux, B; Lucas, C; Marty, M; Piccart, M; Poullain, MG; Soudon, J	1
Koo, HM; Vande Woude, GF	1
Berlion, M; Bourhis, J; Eschwege, F; Frascogna, V; Lucas, C; Maggiorella, L; Poullain, MG; Razy, SD	1
Anstett, M; Atassi, G; Bisagni, E; Casabianca-Pignede, MR; Léonce, S; Perez, V; Pierré, A	1

Trials

1 trial(s) available for s 16020-2 and Neoplasms

Article	Year
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12 Topics: Adult; Aged; Biological Availability; Carbazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Ellipticines; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Risk Assessment; Sensitivity and Specificity; Treatment Outcome	2002

Article

Year

Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.

Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

Topics: Adult; Aged; Biological Availability; Carbazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Ellipticines; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Risk Assessment; Sensitivity and Specificity; Treatment Outcome

2002

Other Studies

3 other study(ies) available for s 16020-2 and Neoplasms

Article	Year
Re: The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. Journal of the National Cancer Institute, 1999, Nov-17, Volume: 91, Issue:22 Topics: Antineoplastic Agents; Apoptosis; Carbazoles; Daunorubicin; Enzyme Inhibitors; Genes, ras; Humans; Neoplasms; Pyridines; Topoisomerase II Inhibitors; Tumor Cells, Cultured	1999
The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Carbazoles; Cell Division; Combined Modality Therapy; Ellipticines; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mouth Mucosa; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Pyridines; Radiotherapy; Stomatitis; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001
In vitro cytotoxicity of S16020-2, a new olivacine derivative. Investigational new drugs, 1996, Volume: 14, Issue:2 Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Division; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Ellipticines; Ethidium; Humans; Isoenzymes; Leukemia L1210; Mice; Neoplasms; Neoplasms, Experimental; Neoplastic Stem Cells; Phenotype; Tumor Cells, Cultured	1996